Table 2.
Clinical trials utilizing adoptive NK cell therapy for lymphoma
| NK Cell Source | Combination Therapy | Disease | Phase | NCT Number | Status | Country |
|---|---|---|---|---|---|---|
| Umbilical Cord Blood NK Cells | AFM13 | CD30+ HL and NHL | Phase I | NCT04074746 | Recruiting | USA |
| Haploidentical NK Cell Enriched DLI | Haploidentical HSCT | NHL, HL, MM, CLL | Phase I | NCT03524235 | Recruiting | USA |
| Umbilical Cord Blood NK Cells | rituximab, Autologous HSCT | NHL | Phase II | NCT03019640 | Recruiting | USA |
| Universal Donor Expanded NK Cells | ALT803 | HL, NHL, AML, MDS, ALL, CML, CLL, Solid Tumors | Phase I | NCT02890758 | Recruiting | USA |
| Natural Killer Cells (Source Unspecified) | rituximab | B Cell Lymphoma | Phase I/II | NCT02843061 | Completed | China |
| Umbilical Cord Blood NK Cells | Umbilical cord blood HSCT +/- rituximab | HL, NHL AML, ALL, MDS, CML | Phase II | NCT02727803 | Recruiting | USA |
| Haploidentical NK Cells | Autologous HSCT | Lymphoma, Neuroblastoma, Solid Tumors | Phase I | NCT02130869 | Completed | USA |
| Haploidentical NK Cell Enriched DLI | Haploidentical HSCT | Lymphoma, AML, ALL, MDS, Neuroblastoma, Rhabdomyosarcoma | Phase I/II | NCT01386619 | Completed | Germany, Switzerland |
| Donor Derived Expanded NK Cells | Allogeneic HSCT | Lymphoma, Leukemia | Phase I | NCT01287104 | Completed | USA |
| NK-92 Cell Line | NHL, HL, Leukemia, Myeloma | Phase I | NCT00990717 | Completed | Canada | |
| Donor Derived NK Cells | Allogeneic HSCT | Lymphoma, Leukemia, MM, MDS, Brain Tumors, Soid Tumors | Phase I/II | NCT00823524 | Completed | Korea |
| Donor Derived NK Cells | Allogeneic HSCT | NHL, HL, ALL, AML, MDS, CLL, CML, Myeloma | Phase I/II | NCT00789776 | Completed | USA |
| Haploidentical NK Cells | Lymphodepleting chemotherapy and IL-2 | NHL, ALL, AML, MDS, CML, JMML | Phase I | NCT00697671 | Completed | USA |
| Haploidentical NK Cells | Autologous HSCT | Lymphoma, Leukemia, Myeloma | Phase I | NCT00660166 | Completed | USA |
| Haploidentical NK Cells | Lymphodepleting chemotherapy and IL-2 | T Cell LLy, ALL, AML, JMML, MDS | Phase I | NCT00640796 | Completed | USA |
| Haploidentical NK Cell Enriched DLI | Haploidentical HSCT | Lymphoma | Phase I | NCT00586703 | Completed | USA |
| Matched Family Donor NK Cell Enriched DLI | Matched Family Donor HSCT | Lymphoma | Phase I | NCT00586690 | Completed | USA |
| Donor Derived NK or T Cells | Allogeneic HSCT with alemtuzumab | Lymphoma, Leukemia | Phase II | NCT00536978 | Completed | USA |
| Donor Derived NK Cells | Allogeneic HSCT, GM-CSF, rituximab | CD20 + NHL, CLL | Phase I | NCT00383994 | Completed | USA |
| Donor Derived NK Cells | Lymphodepleting chemotherapy, rituximab, IL-2 | CD20 + NHL, CLL | Phase I/II | NCT00625729 | Terminated | USA |
| Umbilical Cord Blood NK cells | Lymphodepleting chemotherapy, Lenalidomide, rituximab | Leukemia, Lymphoma | Phase I | NCT02280525 | Active, Not Recruiting | USA |
| Umbilical Cord Blood NK cells | Umbilical cord blood HSCT +/− rituximab | HL, NHL, ALL, AML, MDS, CML, CLL, Myeloma | Phase I | NCT01619761 | Active, Not Recruiting | USA |
NK natural killer, NCT national clinical trial, HSCT hematopoietic stem cell transplant, HL Hodgkin lymphoma, NHL non-Hodgkin lymphoma, AML acute myelogenous leukemia, MDS myelodysplastic syndrome, ALL acute lymphoblastic leukemia, CML chronic myelogenous leukemia, LLy lymphoblastic lymphoma, JMML juvenile myelomonocytic leukemia, IL-2 interleukin-2, CR complete response, PR partial response, MM multiple myeloma, CLL chronic lymphocytic leukemia, DLI donor lymphocyte infusion, GM-CSF granulocyte-monocyte colony-stimulating factor